The efficacy and safety of pramipexole augmentation in treatment resistant depression: Results of the PAX-D trial.

OxTalks is Changing

During Michaelmas Term, OxTalks will be moving to a new platform (full details are available on the Staff Gateway).
For now, continue using the current page and event submission process (freeze period dates to be advised).

If you have any questions, please contact halo@digital.ox.ac.uk

The efficacy and safety of pramipexole augmentation in treatment resistant depression: Results of the PAX-D trial.

There has been interest in the use of dopaminergic agonists in patients with treatment resistant depression (TRD), although they have only been assessed in small-scale, short-term studies. We conducted a substantial RCT examining the effect and safety/tolerability of the dopamine agonist pramipexole in patients with TRD, the PAX-D trial. In this talk I will present the efficacy and safety results from the trial.

This seminar is hosted in person and online, to join online, please use the Zoom details below:

zoom.us/j/93598736019?pwd=tHJ65nmXIrmYTUhi7YRbbdlnyi5Ie6.1
Meeting ID: 935 9873 6019
Passcode: 897963

Date: 4 March 2025, 9:30
Venue:
Department of Psychiatry
Headington OX3 7JX
See location on maps.ox

Details: Seminar Room
Speaker: Professor Michael Browning (Department of Psychiatry, University of Oxford)
Organising department: Department of Psychiatry
Organiser: Rania Elgarf (Department of Psychiatry, University of Oxford)
Organiser contact email address: rania.elgarf@psych.ox.ac.uk
Host: Professor Phil Cowen (Professor of Psychopharmacology, University of Oxford )
Part of: Psychiatry Seminar Series
Booking required?: Not required
Audience: Public
Editor: Rania Elgarf